ABK Biomedical Inc.

🚨 Milestone Alert: ABK Biomedical has completed enrollment in ROUTE90 - the largest prospective FDA IDE trial for Y90 treatment of liver cancer (HCC). 120 patients. One big step closer to FDA approval of Eye90 microspheres. #HCC #LiverCancer #Oncology prnewswire.com/news-releases/…

We are hiring for a Manufacturing Process Development Engineer. Does this sound like you or someone you know? Visit or website or click the link for the job description and further details. linkedin.com/jobs/view/4371…

ABK is proud to share that the first Canadian patient has been successfully treated with Eye90 microspheres® as part of the Route90 clinical trial. A sincere thank you to Dr. Rajvot Dhatt, his outstanding team at Vancouver General Hospital, and all other study contributors.

Did you know it’s Interventional Oncology (IO) Awareness Week? ABK Biomedical is proud to support & contribute to IO with an innovative approach to radioembolization with Eye90 microspheres® and our Route90 clinical trial. ioawarenessweek.org #IKnowIO #Y90 #IOAwarenessWeek

ABK Biomedical Raises US$35M in Series D Financing Grateful for J.P. Morgan Life Sciences Private Capital leading this round, along with our outstanding syndicate of existing investors! prnewswire.com/news-releases/…

The latest article on Y-90 in Radiation Oncology highlights the increasing body of evidence supporting its use in treating patients w/liver cancer. ABK’s anticipated Route90 study results should contribute valuable L1 data to this expanding evidence base. ro-journal.biomedcentral.com/articles/10.11…

As published in a recent JVIR article, Y90 post-procedure PET/SPECT imaging shown to inform better pt. follow-up. Looking forward to seeing how Eye90 microspheres Precision Dosimetry® compares to Y90 PET/SPECT when ABK’s Route90 clinical trial reads out. bit.ly/4g9iNo6

ABK’s timely development of breakthrough Eye90 microsphere technology -- aimed at helping a rapidly growing global liver cancer population: nytimes.com/2025/07/28/wel…

Welcome Dr. Ammar Sarwar as ABK's Route90 pivotal study co-PI!

ABK Biomedical Inc. team focused on our future in China. Special thanks to Eight Roads, Medtronic China, Lei Shi, Delphine Qui, Alex Gu, Michael Wang, Tony Xu. Great strategic assistance from Dr. Dave Liu, Dr. Zhong Qian, Prof Gao-Jun Teng.

Dr. Aravind Arepally demonstrating Eye90 microspheres at 2024 GEST Masterclass:

:"Though these are preliminary results in a limited study with a small number of patients, the results demonstrate that subjects can be treated successfully and safely with Eye90..." Robert Abraham, M.D. Read more: hmpgloballearningnetwork.com/site/iolearnin…

Insights from Society of Interventional Radiology Annual Scientific Meeting: "The new Eye90 microspheres® are glass, but they also have a property that allows us to image them when they are in the body..." Andrew Kennedy, MD Read more: hmpgloballearningnetwork.com/site/iolearnin…

ABK Biomedical's Eye90 microspheres® Route 90 Pivotal Study for treatment of liver cancer featured in SIR Today, Annual Meeting News: irq.sirweb.org/sirtoday #SIR24SLC

ABK Biomedical team featured its breakthrough product at SIR 2024 #SIR24SLC #IRad

We're exhibiting at the SIR 2024 Annual Scientific Meeting at Booth #1228. Connect with us and learn more about our breakthrough device technology and our Route90 FDA IDE study. Join us in advancing patient care!  lnkd.in/dmyA9hyE #SIR24SLC #IRad abkbiomedical.com

Come see us at SIO 2024 - Friday, January 26, 4:05 pm - at the Long Beach Convention Center in Long Beach, California for Discovery Theatre presented by @ABKBiomedical sio-central.org

Listen to ABK Biomedical’s Chief Medical Officer Aravind Arepally and E. Courtney Henry, PhD, Medical Physics discuss Eye90 microspheres for the treatment of unresectable liver cancer on ResearchPod researchpod.org/health-medicin…

ABK Biomedical announces that its Eye90 microspheres® device has been granted Breakthrough Device Designation by t... prn.to/46DZKfq

ABK Biomedical Announces First Patient Treated in its Multi-Center Pivotal Study prnewswire.com/news-releases/…